In vitro activity of Etanidazole against the protozoan parasite Trypanosoma cruzi

AUTOR(ES)

Petray, Patricia B, Morilla, María J, Corral, Ricardo S, Romero, Eder L

FONTE

Memórias do Instituto Oswaldo Cruz

DATA DE PUBLICAÇÃO

2004-03

RESUMO

We investigated the in vitro action of an hydrosoluble 2-nitroimidazole, Etanidazole (EZL), against Trypanosoma cruzi, the etiologic agent of Chagas disease. EZL displayed lethal activity against isolated trypomastigotes as well as amastigotes of T. cruzi (RA strain) growing in Vero cells or J774 macrophages, without affecting host cell viability. Although not completely equivalent to Benznidazole (BZL), the reference drug for Chagas chemotherapy, EZL takes advantage in exertingits anti-T. cruzi activity for longer periods without serious toxic side effects, as those recorded in BZL-treated patients. Our present results encourage further experiments to study in depth the trypanocidal properties of this drug already licensed for use in human cancers.

Documentos Relacionados

• In Vitro Antiproliferative Effects and Mechanism of Action of the New Triazole Derivative UR-9825 against the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi
• In Vitro Antiproliferative Effects and Mechanism of Action of the New Triazole Derivative UR-9825 against the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi
• In vitro evaluation of the activity of aromatic nitrocompounds against Trypanosoma cruzi
• In vitro activity of thienyl-2-nitropropene compounds against Trypanosoma cruzi
• Differential in vitro activity of the DNA topoisomerase inhibitor idarubicin against Trypanosoma rangeli and Trypanosoma cruzi